Lurbinectedin - PharmaMar
Alternative Names: JZP-712; Lurbinectedina - PharmaMar; LY-01017; PM-01183; PM-1183; Tryptamicidin; Zepsyre; ZEPZELCA; ZepzelcaLatest Information Update: 10 Jun 2024
At a glance
- Originator PharmaMar
- Developer ADIUM PHARMA; Immedica; Jazz Pharmaceuticals plc; Luye Pharma Group; PharmaMar; Roche; Specialised Therapeutics Asia; Swiss Group for Clinical Cancer Research
- Class 3-ring heterocyclic compounds; Acetates; Alkaloids; Antineoplastics; Carbolines; Dioxolanes; Indoles; Small molecules; Spiro compounds; Tetrahydroisoquinolines
- Mechanism of Action Alkylating agents; DNA damage stimulants
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
- New Molecular Entity Yes
Highest Development Phases
- Marketed Small cell lung cancer
- Phase III Ovarian cancer
- Phase II/III Leiomyosarcoma
- Phase II Breast cancer; Malignant-mesothelioma; Non-small cell lung cancer; Pancreatic cancer; Sarcoma; Solid tumours
- Phase I/II Ewing's sarcoma; Soft tissue sarcoma
Most Recent Events
- 04 Jun 2024 Efficacy and adverse events data from the phase III LAGOON trial in Small cell lung cancer presented at the American Society of Clinical Oncology meeting (ASCO-2024)
- 31 May 2024 Efficacy and adverse event data from a phase I/II trial in Solid tumors presented at the 60th Annual Meeting of the American Society of Clinical Oncology (ASCO-2024)
- 01 May 2024 Phase-III clinical trials in Small cell lung cancer (Monotherapy, Second-line therapy or greater) in Japan, Taiwan, Turkey (IV) (NCT05153239)